[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"respiratory-tract-infections-rti\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:respiratory-tract-infections-rti":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,58,88,123,157,185,223,244,274,304,332],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":36,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":4},"100638958","immune-mitochondrial-correction-in-military-recruits-100638958",false,"NCT07622147","Immune-Mitochondrial Correction in Military Recruits","A Parallel-Group, Participant-Blinded Comparative Trial of an Immuno-Mitochondrial Correction Strategy (Sodium Nucleinate + Magnesium\u002FPyridoxine + Vitamin D3 5000 IU) Versus Standard Multivitamin Prophylaxis to Reduce Respiratory Infection Incidence in Male Military Recruits During the 6-Month Adaptation Period","IMMU-MITO","Inclusion Criteria:\n\n* Male military recruits aged 18-27 years\n* Starting initial military training at the Military Clinical Hospital of the Ministry of Defense of the Republic of Kazakhstan (Almaty)\n* Signed informed consent\n* No acute infectious diseases at enrollment\n* Willingness to comply with the study protocol for 6 months\n* Absence of any exclusion criteria\n\nExclusion Criteria:\n\n* Chronic immunodeficiency states (HIV infection, congenital immunodeficiencies, current immunosuppressive therapy)\n* Severe chronic diseases in decompensation stage (diabetes mellitus, renal failure, hepatic failure, heart failure)\n* Allergy or hypersensitivity to any components of the study interventions (multivitamin, sodium nucleinate, magnesium, vitamin B6, vitamin D)\n* Use of vitamin-mineral complexes or immunomodulators within the last 3 months prior to enrollment\n* Hypercalcemia (serum calcium \\>2.6 mmol\u002FL) or history of urolithiasis\n* Hypermagnesemia (serum magnesium \\>1.1 mmol\u002FL)\n* Sarcoidosis or other granulomatous diseases\n* Refusal or inability to provide informed consent",true,"MALE","18 Years","27 Years",{"count":22,"type":23},200,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this clinical trial is to learn if a new immune-mitochondrial correction strategy works better than standard vitamins to prevent infections in young male military recruits during their first 6 months of service.\n\nThe main questions it aims to answer are:\n\n1. Does the new strategy lower the number of recruits who get infections (like colds, flu, or pneumonia) over 6 months?\n2. Does the new strategy improve how well the immune cells work, specifically their mitochondria (the power source inside cells)?\n\nResearchers will compare:\n\n* Control group (100 participants): Standard multivitamin taken once a day for 30 days\n* Experimental group (100 participants): New strategy (sodium nucleinate, magnesium, vitamin B6, and vitamin D 5000 IU) taken as 3 tablets once a day for 30 days to see if the new strategy lowers infection rates more than standard vitamins.\n\nWho can take part:\n\nHealthy male military recruits aged 18-27 years who are starting their initial training at the Military Clinical Hospital in Almaty, Kazakhstan.\n\nWhat participants will do:\n\nParticipants will be placed into one of the two groups by chance (like flipping a coin). They will:\n\n* Take study pills once a day for 30 days\n* Have blood draws 3 times over 6 months (baseline, 1 month, and 6 months)\n* Have daily health checks by medical staff\n* Complete quality of life questionnaires\n\nWhat we will measure:\n\n* Number of participants who get infections during 6 months\n* How well the mitochondria in immune cells work (from blood samples)\n* Immune system status\n* Stress and adaptation levels\n* Vitamin D and other blood markers\n\nRisks and benefits:\n\nThe risks are very low. Participants may have mild discomfort or a small bruise from blood draws. All study pills are approved and registered in Kazakhstan.\n\nThere is no direct benefit to participants, but they will receive extra medical monitoring. The indirect benefit is helping develop a better prevention program to protect future recruits.\n\nWhere the study is taking place:\n\nMilitary Clinical Hospital of the Ministry of Defense of the Republic of Kazakhstan, Almaty, Kazakhstan.\n\nStudy duration:\n\nJanuary 2027 to December 2028.",[29,30,31,32,33,34,35],"Respiratory Tract Infections (RTI)","Meningitis","Primary Prevention\u002FMethods","Primary Prevention","Mitochondrial Biomarkers","Immuno-monitoring","Immuno-modulation",[37,38,39,40,41,42,43,44,45],"Military recruits","Infection prevention","Immunocorrection","Mitochondrial function","Sodium nucleinate","Vitamin D","Respiratory infections","Stress adaptation","Randomized controlled trial","NOT_YET_RECRUITING","2026-06-24",{"date":49,"type":50},"2026-06-29","ACTUAL",{"date":52,"type":23},"2027-01-01",{"date":54,"type":23},"2028-12",{"name":56,"class":57},"MIPO Clinic","OTHER",{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":65,"minAge":4,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":87},"100639061","virological-surveillance-of-acute-respiratory-infection-in-primary-health-care-in-metropolitan-france-100639061","NCT07599449","Virological Surveillance of Acute Respiratory Infection in Primary Health Care in Metropolitan France","RS-viro IRA","Inclusion Criteria:\n\n* be seen by a general practitioner or pediatrician participating in the Sentinelles surveillance program;\n* between week 40 (late September-early October) and week 15 (mid-April) of each year\n* have an acute respiratory infection (ARI) as defined below: Sudden onset of fever (or feeling of fever) and respiratory symptoms\n* have given oral consent to participate in this monitoring or, in the case of minors, oral consent given by the child's legal guardian(s) present at the consultation\n\nExclusion Criteria:\n\n* a person who is subject to a court-ordered protective measure;\n* a person who is under guardianship or conservatorship, unless accompanied by their legal guardian or unless the legal guardian objects to their participation;\n* a person who is not in a condition to receive information or give consent.","ALL",{"count":67,"type":23},25000,"OBSERVATIONAL","Every year in the fall and winter, numerous respiratory viruses (such as influenza viruses, SARS-CoV-2 (COVID-19), RSV, rhinovirus, and metapneumovirus) circulate in mainland France, causing acute respiratory infections (ARIs). These viruses can cause epidemics of varying severity, requiring close monitoring to determine their circulation levels and adapt public health measures accordingly. In France, ARI surveillance relies on two networks: the Sentinelles network in primary care and the RENAL network in hospitals. The Sentinelles surveillance is conducted in collaboration with Santé publique France, the National Reference Center for Respiratory Infection Viruses (Institut Pasteur and Hospices Civils de Lyon), and the University of Corsica. As part of the virological surveillance of ARIs, Sentinelles physicians are asked to collect nasopharyngeal swabs or saliva samples from a sample of patients presenting with an ARI during their clinic visits. This surveillance makes it possible to identify respiratory viruses circulating in primary care (general practice and pediatrics), to describe confirmed cases for each of the circulating viruses, and to estimate the impact of each on general practice. This surveillance also allows for the evaluation of the effectiveness of vaccines against influenza and COVID-19.",[29,71,72,73,74,75,76],"Influenza -Like Illness","Influenza","COVID - 19","RSV Infections","Rhinovirus Infection","Metapneumovirus Infection","2026-06-03",{"date":79,"type":50},"2026-06-05",{"date":81,"type":23},"2026-05-15",{"date":83,"type":23},"2031-05-20",{"name":85,"class":86},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":17,"sex":65,"minAge":19,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":24,"phases":98,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100589391","optimal-implementation-of-antimicrobial-stewardship-in-general-practice-100589391","NCT06953804","Optimal Implementation of Antimicrobial Stewardship in General Practice","Optimal Implementation of Antimicrobial Stewardship in General Practice (OPTIMAS-GP) Study: A Hybrid Type 3 Implementation Trial","OPTIMAS-GP","Study sites\n\nInclusion Criteria:\n\n1. New South Wales, Queensland, Tasmania, or Victoria\n2. at least two GPs per practice consent to be in the study,\n3. that at least one member of practice staff consents to be in the study\n4. that a staff member from the site will be available to provide 90 minutes per fortnight of administrative support for the study. There are no exclusion criteria in addition to this.\n\nExclusion Criteria: None\n\nParticipating doctors and healthcare workers\n\nInclusion criteria:\n\n1\\) Working at a participating practice for at least three days a week. Exclusion criteria : None\n\nPatients completing patient reported outcome measure survey\n\nInclusion criteria:\n\n1. patients consulted with a participating GP for a RTI,\n2. patients re-consulted with a GP or was hospitalized. Exclusion criteria: None\n\nPatient reported experience measures survey\n\nInclusion criteria:\n\n1\\) patient consulted with a participating GP for an RTI. Exclusion criteria: None\n\nPatients participating in interviews as part of the nested case studies\n\nInclusion criteria:\n\n1. consulted with a participating GP for a RTI,\n2. completed a patient survey,\n3. able to read and speak English Exclusion criteria: None",{"count":97,"type":23},120,[26],"This trial aims to increase the use of antimicrobial stewardship resources when treating patients with respiratory tract infections. This trial is set in Australian general practices (family medicine or primary care).\n\nThe main question it aims to answer is which type of implementation activities increase the use of antimicrobial stewardship resources. Researchers will compare doctors who receive face-to-face implementation activities (the Integrated Network group) to those who received virtual or online activities (the Virtual Network group). The primary hypothesis is that there will be a difference in how often interventions are used\n\nParticipating doctors will be asked to record how often they use antimicrobial stewardship resources and which interventions they prefer. Participating practices will also provide researchers data on how many patients the doctors see.\n\nPatients with respiratory tract infections who saw a participating doctor will be asked to give feedback on their experience using surveys. A subgroup of doctors, practice staff, and patients will interviewed about their experience in the study.",[101,29],"The Use of Antimicrobial Stewardship in in General Practice (Family Medicine)",[103,104,105,106,107,108,109,110,111],"hybrid type 3 implementation trial","cluster randomised control trial","antimicrobial stewardship","antibiotic stewardship","respiratory tract infections","general practice","family medicine","primary care","Australia","RECRUITING","2026-05-07",{"date":115,"type":50},"2026-05-12",{"date":117,"type":50},"2025-07-01",{"date":119,"type":23},"2028-06-30",{"name":121,"class":57},"University of Wollongong",4,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":17,"sex":65,"minAge":131,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":24,"phases":135,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":156},"100637512","phase-4-prevention-with-ismigen-of-rtis-in-kids-100637512","NCT07578012","Prevention With Ismigen of RTIs in Kids","A Randomized Double-blind Placebo-controlled Study to Demonstrate the Efficacy of PMBL® Sublingual Tablets in Reducing the Incidence of Respiratory Tract Infections in Children Aged 3-12 Years (PIRTIK).","PIRTIK","Inclusion Criteria:\n\n1. Children of both genders aged from 3 to 12 years.\n2. Written informed consent obtained from the parents\u002Flegally authorized representatives\n3. Written assent obtained from the subject from 7 years\n4. Subject presenting with a susceptibility to respiratory tract infections according to the investigator\n5. No respiratory tract infection within 15 days before the randomization visit\n6. All girls of childbearing potential have a negative pregnancy urine testing at randomization visit and are informed and their parents as well of the requirement for contraception during the study.\n7. A cooperative attitude and ability to correct use of PMBL® tablet.\n\nExclusion Criteria:\n\n1. Subject treated with bacterial lysates within the previous 6 months prior to V1 or ongoing treatment.\n2. Body temperature ≥ 37.5°C at the randomization visit.\n3. Pregnant\u002FLactating female or with sexual activity without hormonal contraception, intrauterine device or barrier methods.\n4. Primary or secondary immunodeficiency, cystic fibrosis, bronchiectasis, alpha-1 antitrypsin deficiency, malignancy, endocrinological diseases or other chronic respiratory diseases, except asthma and allergic rhinitis.\n5. Known sensitivity to the components of study medication.\n6. Any major surgery within the last 3 months prior to study enrolment or planned to occur within the duration of study.\n7. Treatment with the following medications:\n\n   1. Injection or oral administration of steroids within 4 weeks prior to study enrolment.\n   2. Previous and\u002For concomitant immunosuppressants, immunostimulants, allergen-immunotherapy or gamma globulins within 6 months prior to study enrolment.\n8. Inability to understand or comply with study procedures or with study treatment intake.\n9. Subject participating in another interventional clinical study at the time of screening visit.","3 Years","12 Years",{"count":134,"type":23},224,[136],"PHASE4","Although the efficacy of PMBL® sublingual tablets is evident to most prescribers, the clinical studies available to demonstrate the efficacy of this bacterial lysate in preventing recurrent respiratory tract infections have undeniable methodological biases. To demonstrate the efficacy of PMBL® in the pediatric population without questionable bias, a randomized double-blind Placebo-controlled study will be conducted: one arm of children presenting with a risk of recurrent respiratory tract infections will be treated with PMBL® for a 3-month period, 10 days per months during the fall-winter whereas subjects of the Placebo arm will receive sublingual tablet indistinguishable from PMBL® but without active ingredients. Both groups of subjects will be followed for four additional months. To improve the accuracy of data and the tracking of respiratory tract infections (RTI), a diary will be provided to each subject, allowing them to report the event as soon as it occurs. If necessary, a visit may be planned to enable the investigator to assess the event accurately.",[29,139],"Healthy Children",[29,141,142,143,144,145],"Bacterial Lysates","PMBL® sublingual tablets","Recurrent Respiratory Tract Infections","Ismigen","Incidence","2026-05-05",{"date":148,"type":50},"2026-05-11",{"date":150,"type":23},"2026-05",{"date":152,"type":23},"2027-04",{"name":154,"class":155},"Lallemand Pharma AG","INDUSTRY",8,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":17,"sex":65,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":24,"phases":168,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":4},"100629801","phase-4-impact-of-ahcc-supplementation-for-prevention-of-respiratory-tract-infections-among-children-age-2-4-years-old-100629801","NCT07479394","Impact of AHCC® Supplementation for Prevention of Respiratory Tract Infections Among Children Age 2-4 Years Old","A Double-Blind, Randomized, Placebo-Controlled Trial of AHCC® Supplementation for Prevention of Respiratory Tract Infections Among Children Age 2-4 Years Old","Inclusion Criteria:\n\n1. Children aged 2-4 years old at the time of enrolment\n2. Good nutritional status with weight-for-height \\> -2, and height-for-age z-score \\> -2 based on WHO growth standards\n3. Infants in a group setting (daycare centers).\n4. No congenital disorder\n5. Not suffering from severe coughing or diarrhoea at the time of recruitment\n6. Written informed consent will be obtained from parents or legal guardians before enrollment.\n\nExclusion Criteria:\n\n* Presence of chronic illnesses or conditions (congenital disorder, genetic syndromes, congenital heart disease, chronic renal failure, cystic fibrosis, etc)\n* Children who have participated in another clinical intervention study within the past 30 days.\n* Children who are likely to be transferred to another facility that is not part of the study before completing the follow-up period","2 Years","4 Years",{"count":167,"type":23},60,[136],"This is a study to evaluate the effects of a prebiotic, AHCC, a standardized extract of cultured Lentinula edodes mycelia, on immunologic markers and the incidence of respiratory tract infections in children.",[29],[172,173,174,175],"AHCC","Lentinula edodes mycelia","prebiotic","respiratory tract infection (RTI)","2026-03-16",{"date":178,"type":50},"2026-03-18",{"date":180,"type":23},"2026-06-01",{"date":182,"type":23},"2026-12-31",{"name":184,"class":57},"Hasanuddin University",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":65,"minAge":192,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":24,"phases":196,"briefSummary":197,"conditions":198,"keywords":201,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":222},"100627844","clinical-assessment-of-respiratory-events-for-kids-integrating-diagnostics-and-stewardship-100627844","NCT07453914","Clinical Assessment of Respiratory Events for Kids: Integrating Diagnostics and Stewardship","CARE4KIDS","Inclusion Criteria:\n\n* Children from 60 days until less than 18 years old with signs and\u002For symptoms leading to suspicion of Respiratory Tract Infection (RTI) and\u002For Influenza-Like Illness (ILI), such as fever (Temperature greater than or equal to 37.8°C), rhinorrhea, nasal obstruction, sneezing, sore throat of pharyngeal pain, difficulties in breathing and\u002For cough, tachypnea, shortness of breath, apnea, croup.\n* Children and his\u002Fher legal representative who provide their informed consent.\n* Patients willing to provide a Nasopharyngeal Swab (NPS).\n\nExclusion Criteria:\n\n* Any condition that, in the opinion of the investigator\u002Fnurse results in significant immune dysfunction such as known primary immunodeficiency disorder, ongoing immunosuppressive therapy, known HIV infection, active or recent oncologic disease, transplant recipients and\u002For chronic use of immunomodulating agents,\n* Any condition that, in the opinion of the investigator\u002Fnurse, is related to severe patients requiring urgent referral who need to go on intensive care (such as patients who have a diagnosis of sepsis or septic shock,\n* Known pregnancy\n* Patients who refused to participate in the study and therefore declined Informed Consent Form.","60 Days","17 Years",{"count":195,"type":23},720,[26],"This study, called Care4Kids, aims to improve the management of respiratory infections in children visiting emergency departments. The research will evaluate the impact of using the BIOFIRE® SPOTFIRE® R\u002FST Panel, a rapid molecular point-of-care test, compared to standard care.\n\nChildren aged 2 months to 18 years with symptoms of respiratory tract infection or flu-like illness will be enrolled. After consent, participants will be randomly assigned to one of two groups:\n\n* Intervention group: The SPOTFIRE test will be performed immediately to guide treatment decisions.\n* Control group: Patients will receive standard care without the rapid test. The study will take place in three pediatric emergency departments in France, Greece, and Sweden. Up to 720 children will participate. A follow-up phone call will be made 14 days after the visit to check recovery and satisfaction.\n\nThe goal is to see whether rapid testing improves patient outcomes, reduces unnecessary treatments, and increases caregiver satisfaction.",[29,199,200],"Influenza-like Illness","Children",[202,203,204,205,206,207,208,209,210,211,212],"Respiratory Tract Infection","Pediatric Respiratory Disease","Viral Respiratory Infection","Bacterial Respiratory Infection","children","Pediatrics","Stewardship","Diagnostic","Multicenter Study","Point Of Care Testing","multiplex Polymerase Chain Reaction.","2026-03-03",{"date":215,"type":50},"2026-03-06",{"date":217,"type":23},"2026-03",{"date":219,"type":23},"2026-09",{"name":221,"class":155},"BioMérieux",3,{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":65,"minAge":19,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":24,"phases":232,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":87},"100623849","the-influence-of-explainability-and-integrability-of-ai-cdss-on-usage-behavior-among-primary-care-physicians-100623849","NCT07401979","The Influence of Explainability and Integrability of AI-CDSS on Usage Behavior Among Primary Care Physicians","Inclusion Criteria:\n\n1. Be currently employed full-time in clinical practice at a primary care facility, including community health centers, community health stations, township hospitals, or village clinics;\n2. Hold a clinical medical license with a specialty in general practice or internal medicine, and have experience in diagnosing and managing respiratory tract infections;\n3. Have at least one year of clinical work experience;\n4. Be proficient in basic computer use (e.g., web browsing and online questionnaire completion), have reliable internet access, and be capable of independently completing the online experimental tasks;\n5. Provide voluntary informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Non-clinical staff (e.g., administrative personnel, pharmacists, laboratory technicians, or public health workers who do not directly provide outpatient clinical care);\n2. Individuals unable to independently complete the online experimental procedure or who demonstrate significant difficulty understanding the task instructions.","65 Years",{"count":231,"type":23},3000,[26],"The goal of this observational experimental study is to determine how system-level features of artificial intelligence clinical decision support systems (AI-CDSS)-specifically explainability and integrability-affect usage behavior among primary care physicians in China. The study focuses on licensed primary care physicians, regardless of gender, age, years of clinical experience, or prior AI exposure.\n\nThe main questions it aims to answer are:\n\n* Do specific AI features (e.g., feature attribution, chain-of-thought explanation, seamless workflow integration, automated data input) independently influence physicians' adoption intention, diagnostic accuracy, and their perceptions of the system's usefulness and ease of use?\n* Do pairwise combinations of these AI features produce significant interaction effects-either synergistic or antagonistic-on these outcomes? Researchers will compare 32 distinct AI interface configurations generated from a 2⁶-¹ fractional factorial design (Resolution VI), each representing a unique combination of six binary AI features: (A) gradient-based feature importance (0 = absent, 1 = present), (B) chain-of-thought reasoning (0\u002F1), (C) workflow integration (0 = multiple pop-up alerts, 1 = unified sidebar display), (D) automated data extraction (0 = manual entry, 1 = auto-populated from case text), (E) recommendation scope adapted to primary care settings (0 = restricted to essential options, 1 = full range of recommendations), and (F) model confidence display (0 = absent, 1 = present). This design enables unbiased estimation of all six main effects and all 15 two-way interactions.\n\nParticipants will:\n\nComplete three standardized clinical case scenarios involving common respiratory infections via a web-based simulation platform; First provide an initial diagnosis and treatment plan without any AI input; Then review an AI-generated recommendation embedded with a randomly assigned combination of the six AI features; Revise their final diagnosis and prescription based on the AI suggestion; Rate their adoption intention, perceived usefulness, and perceived ease of use using validated 7-point Likert-scale items after each case.",[29],"2026-02-03",{"date":237,"type":50},"2026-02-11",{"date":239,"type":23},"2026-02-05",{"date":241,"type":23},"2026-04-20",{"name":243,"class":57},"Huazhong University of Science and Technology",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":252,"minAge":253,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":257,"conditions":258,"keywords":260,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":272,"locationsCount":87},"100615457","comparing-and-predicting-the-risk-of-respiratory-tract-infection-rti-among-post-menopausal-women-on-or-without-hormone-replacement-therapy-hrt-an-observational-cohort-study-100615457","NCT07292857","Comparing and Predicting the Risk of Respiratory Tract Infection (RTI) Among Post-menopausal Women on or Without Hormone Replacement Therapy (HRT): an Observational Cohort Study","Comparing and Predicting the Risk of Respiratory Tract Infection (RTI) Among Post-menopausal Women on or Without Hormone Replacement Therapy (HRT): an Observational Cohort Study (Meno_Flu)","Meno_Flu","Inclusion Criteria:\n\n* Biological sex: female\n* Age: 40-60 years\n* Self-determined decision to participate, confirmed by signing the informed consent form (ICF)\n* Fluent in German\n* Agreement to wear a smartwatch (Garmin Vivosmart 5) for most of the time over six months\n* Ownership of a smartphone compatible with the Fitrockr application\n* Confirmed post-menopausal status: Spontaneous amenorrhea for ≥12 consecutive months without other causes OR ≥6 months of spontaneous amenorrhea with biochemical confirmation (FSH \\> 40 IU\u002FL OR FSH \\> 30 IU\u002FL for women aged ≥50 using hormonal contraception) OR bilateral oophorectomy ≥6 weeks before enrollment\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Known allergic reaction to polycarbonate (smartwatch wristband material)\n* Asthma not well-controlled (ACT score \\\u003C20 despite medication)\n* Use of injectable asthma drugs with broad immunomodulatory activity\n* Coronary artery disease\n* Diagnosis of diabetes mellitus\n* Cancer diagnosis\n* Diagnosis of chronic kidney disease\n* Confirmed diagnosis of familial hypercholesterolemia (genetic)\n* Sleep apnea managed with bi-level positive airway pressure (PAP)\n* Chronic rhinosinusitis\n* Severe (stage 3 or 4) chronic obstructive pulmonary disease (COPD) or interstitial lung disease with hospitalization within the prior 12 months for respiratory symptoms\n* Any other condition\u002Ftreatment deemed incompatible with the study objectives by the PI or delegated co-investigators\n* Current employment in the Section of Gynecological Endocrinology and Reproductive Medicine (Inselspital Bern) or any other relation to the principal investigator\n* Concurrent participation in a clinical interventional study\n* Technical inability to pair the participant's smartphone with the smartwatch\n* Inability to comply with study procedures (e.g., due to language, psychiatric illness, or inability to attend study site)","FEMALE","40 Years","60 Years",{"count":256,"type":23},400,"Background: Respiratory tract infections (RTIs) are a major public health concern. Global studies published in Lancet Infect. Dis. highlight the persistent morbidity and mortality from RTIs, with upper- and lower-RTIs collectively accounting for more than 100 million disability-adjusted-life-years per year.\n\nDuring menopause, hormonal changes alongside other factors increase the risk for illnesses, such as RTIs, COPD, cardiovascular disease, and diabetes. However, it remains unknown how hormone-replacement therapy during menopause might impact the frequency or severity of RTIs. While hormone replacement therapy (HRT) is often prescribed for menopausal symptom relief, its potential impact on RTI risk and severity has not been examined.\n\nObjective: This observational cohort study aims to compare and predict the risk of RTI among postmenopausal women, with a particular focus on the influence of HRT. The principal aim is to compare the rates and severity of respiratory tract infections in postmenopausal women taking or not taking HRT. The secondary aims are to characterize risk factors for RTI in postmenopausal women and identify signals in wearable data that predict the onset of an RTI before symptoms become apparent.\n\nMethods: 400 women aged 40-60 will be studied, stratified into two groups: postmenopausal women taking HRT, and postmenopausal women not taking HRT. Participants will each be followed for six months, with RTI episodes recorded through self-reporting and confirmed by laboratory tests. Wearable devices will continuously monitor physiological parameters (e.g., heart rate, sleep patterns), and questionnaires will assess lifestyle factors, medical history, and environmental exposure. Statistical modeling and machine learning approaches will be used to analyze infection predictors and develop a model that predicts the risk of onset of an RTI.\n\nImpact: Half of the world's population inevitably undergoes menopause, and this important life transition has wide-ranging impacts on women's health and quality of life for decades. Studies show that women spend more of their lives in poor health than men, with far-reaching impacts on a woman's participation in society, career performance, and ability to care for other family members. A better understanding of risk factors for respiratory infections in menopausal women and whether hormone-replacement therapy influences RTIs will contribute much-needed knowledge to enable better health management strategies for women. Furthermore, an \"early-warning\" system based on wearable signals will provide a valuable tool for quick intervention and to reduce the spread of infectious illnesses. Such an \"early-warning\" system will subsequently be tested for applicability across a broader representation of society as a preventive health measure and tool for pandemic preparedness.\n\nConclusion: Findings will enhance understanding of RTI risk and management in menopausal women and contribute to the development of personalized prevention strategies. Future applications include a wearable-based medical device for real-time RTI risk assessment, potentially reducing antibiotic overuse and improving healthcare efficiency. By enabling early detection and risk stratification, this study paves the way for a proactive and personalized approach to respiratory health in postmenopausal women, ultimately shifting the focus to prevention.",[259,29],"Menopausal Women",[261,262,263,264,265],"Hormone Replacement Therapy","Menopause","Health monitoring","Wearables","Infection risk","2025-12-05",{"date":268,"type":50},"2025-12-18",{"date":270,"type":50},"2024-09-18",{"date":217,"type":23},{"name":273,"class":57},"Insel Gruppe AG, University Hospital Bern",{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":17,"sex":65,"minAge":4,"maxAge":282,"enrollmentInfo":283,"targetDuration":285,"studyType":68,"phases":4,"briefSummary":286,"conditions":287,"keywords":291,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":303},"100612162","respiratory-infections-in-young-children-100612162","NCT07249996","Respiratory Infections in Young Children","Respiratory Infections in Young Children in Colombia and Panamá: Epidemiology, Interactions, and Long-term Consequences.","MINERVAL","Inclusion Criteria:\n\n* Newborns younger than 29 days of life, with or without pre-existing conditions\n* Infants whose parent(s) or guardian(s) are available for telephone contact for the duration of the study, and do not intend to relocate outside of the study area, to ensure adherence to RTI and in-person visits.\n* Infants whose parent(s) or guardian(s) provide informed consent to participate in the study.\n* Infants whose parent(s) or guardian(s) are willing to authorize data and specimen collection, storage and analysis.\n\nExclusion Criteria:\n\n* Infants born to a pregnant mother under 14 years of age (under Colombian law, pregnancies occurring in individuals younger than 14 years of age are legally presumed to result from sexual abuse).","29 Days",{"count":284,"type":23},1088,"5 Years","The goal of this observational study is to learn about the causes, severity, and long-term effects of respiratory tract infections (RTIs) in young children from birth to five years of age in Colombia and Panamá. The main questions it aims to answer are:\n\nHow often do respiratory infections occur in children under two years old, and which viruses or bacteria cause them? Why do some children develop more severe infections than others? Do early infections or vaccinations change how the immune system responds to future illnesses? How do viruses and bacteria interact in the respiratory tract to influence disease severity and long-term respiratory health? Researchers will follow newborns from birth until age five to understand how respiratory infections develop and affect children's health over time. Participants will not receive any experimental treatment.\n\nFamilies who join the study will:\n\nBe contacted twice a week through a phone app or phone calls to check for symptoms of respiratory infection.\n\nAttend in-person visits if their child becomes ill and every six months for routine follow-up.\n\nProvide nasal and blood samples during illness episodes so researchers can identify the viruses or bacteria causing infection and study how the immune system responds.\n\nThis study began in May 2024 and is being conducted in Cali, Colombia, and Panamá City, Panamá. The research team plans to continue to include participants and continue active follow-up until the children reach five years of age.\n\nThe information collected will help scientists and health professionals understand how different pathogens cause respiratory infections, what factors increase the risk of severe illness, and how early infections may influence long-term lung health. The study's findings will support future efforts to prevent and treat respiratory diseases in young children.",[29,288,289,290],"Lower Respiratory Tract Infection (LRTI)","Viral Infections","Cohort Study",[292,293,200],"Birth Cohort Study","Respiratory Tract Infection (RTI)","2025-11-24",{"date":296,"type":50},"2025-11-25",{"date":298,"type":50},"2024-05-02",{"date":300,"type":23},"2031-12-30",{"name":302,"class":57},"Eduardo Lopez -Medina",2,{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":65,"minAge":4,"maxAge":312,"enrollmentInfo":313,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":315,"conditions":316,"keywords":318,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":303},"100585425","to-evaluate-mucosal-and-systematic-immune-response-to-acute-respiratory-tract-infections-of-south-african-children-100585425","NCT06902194","To Evaluate Mucosal and Systematic Immune Response to Acute Respiratory Tract Infections of South African Children","Mucosal Surveillance and Immunology of Respiratory Pathogens in South African Children Post the COVID-19 Pandemic","Muco-Kids","Inclusion Criteria:\n\n\\- Children aged 0-13 years with acute respiratory tract infections presenting to Tygerberg Hospital (TBH) in Cape Town, South Africa, for routine care\n\nExclusion Criteria:\n\n* Admitted for \\\u003C 72 hours","13 Years",{"count":314,"type":23},250,"The goal of this observational study is to answer a few questions about respiratory tract infections in South African children:\n\n1. How do children with COVID-19 and other respiratory (chest, throat, ear or nose) germs show symptoms? What signs should be looked for, and which children are more likely to get seriously ill? Are there any new germs that haven't been discovered yet? Can immune cells in saliva predict which children will get more severe disease?\n2. The body's immune response (soldier- cells) in blood and saliva (spit) will be studied.\n3. What is the short-term effect of COVID-19 and other respiratory viruses\u002F germs on the breathing (lung function) of children?\n4. What is the impact of respiratory germs on the quality of life in children and their families? The investigators aim to recruit a minimum of 250 children with respiratory pathogens.",[29,317],"Mucosal Immunity",[319,320,321,322],"Mucosal immunity","Mucosal immunology","Respiratory tract infections","Saliva","2025-03-28",{"date":325,"type":50},"2025-03-30",{"date":327,"type":50},"2024-10-23",{"date":329,"type":23},"2025-11",{"name":331,"class":57},"Desmond Tutu TB Centre",{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":65,"minAge":339,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":24,"phases":342,"briefSummary":343,"conditions":344,"keywords":345,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":87},"100566445","phase-4-om-85-to-prevent-respiratory-infections-in-older-at-risk-patients-100566445","NCT06655272","OM 85 to Prevent Respiratory Infections in Older At Risk Patients","OM85OLDER","Inclusion Criteria:\n\n* Age 75 years or older\n* At least 2 RTIs in the year prior to enrollment\n* Patients must have been residing in nursing homes for at least 6 months and have an estimated length of stay in nursing homes of at least 6 months by their treating physician.\n* Signed informed consent. If participants are unable to provide informed consent due to cognitive impairment, consent will be provided by a legally recognized representative or trustee of the patient (pursuant to Article 4 of Law No. 219 of December 22, 2017).\n* Have a life expectancy of at least one year in the judgment of their treating physician.\n\nExclusion Criteria:\n\n* Patients with known allergy or previous intolerance to any component (including the excipient) of the study drug\n* Patients with active neoplasia and prognosis of less than one year\n* Patients with previous organ transplantation\n* Patients treated with prohibited drugs (see Table 1) in the 3 months prior to the start of the study\n* Patients who have taken bacterial lysates in the 6 months prior to enrollment or are currently using them\n* Patients regularly treated with oral corticosteroids\n* Patients unable to follow instructions and unreliable patients (including patients with alcoholism or patients unwilling to give informed consent or comply with protocol requirements)\n* Patients with any other clinical condition that, in the opinion of the investigator, would not allow completion of the protocol and safe administration of the study drugs","75 Years",{"count":341,"type":23},360,[136],"People living in NH are at higher risk of respiratory infections compared to their counterpart living in the community. Products obtained from dead bacteria (\"bacterial lysate\") can be used to boost immune system and may reduce the risk of respiratory infections. Very little information is available on the effect of these substances in older people. This study will evaluate the efficacy of a bacterial lysate in reducing the incidence of lower respiratory tract infections in older people living in nursing homes. The study will include a treatment arm, in which participants will received the lysate, and a control arm in which participants will received a matching placebo (i.e., a pill that has the same appearance of the lysate but does not contain the lysate itself).",[29],[346,347,348],"Older people","Nursing home","Bacterial lysate","2025-03-14",{"date":351,"type":50},"2025-03-18",{"date":353,"type":50},"2025-02-01",{"date":355,"type":23},"2026-04",{"name":357,"class":57},"Campus Bio-Medico University"]